Agenus is a clinical-stage biopharmaceutical company developing monoclonal antibody-based therapeutic products for cancer and autoimmune diseases, including bispecific antibodies and adoptive cell therapies. The company's lead programs focus on combining anti-PD-L1 and anti-ICOS antibodies for solid tumors and other oncology and immunotherapy indications, with revenue potential dependent on successful regulatory approval, commercialization, and third-party reimbursement coverage. Agenus pursues partnerships with institutional and corporate collaborators and outsources manufacturing to contract manufacturers, targeting approval pathways in the United States and European Union while generating no product revenues in its current development stage.